<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03495817</url>
  </required_header>
  <id_info>
    <org_study_id>ATI-50002-AGA-201</org_study_id>
    <nct_id>NCT03495817</nct_id>
  </id_info>
  <brief_title>A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution</brief_title>
  <official_title>An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aclaris Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aclaris Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female
      subjects with androgenetic alopecia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study designed to evaluate the safety and efficacy of ATI-50002 Topical
      Solution in male and female subjects with androgenetic alopecia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from Baseline in Target Area Hair Count (TAHC)</measure>
    <time_frame>Week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cumulative Target Area Hair Width</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of new hair growth using a seven-point rating scale</measure>
    <time_frame>Week 26</time_frame>
    <description>Subjects and Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Open Label ATI-50002 Topical Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATI-50002</intervention_name>
    <description>ATI-50002 Topical Solution</description>
    <arm_group_label>Open Label ATI-50002 Topical Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male subjects and non-pregnant, non-nursing female subjects 18-50 years of age with a
        clinical diagnosis of androgenetic alopecia.

        Subjects willing to agree to have a small circle of hair clipped to approx. 1mm in length
        on their balding spot.

        Subjects willing to agree to have a permanent dot tattoo applied to their scalp to mark the
        center of the identified target area.

        Subjects must agree to maintain the same hair style and hair care regimen during the study.

        Exclusion Criteria:

        Females who are nursing, pregnant, or planning to become pregnant for the duration of the
        study and up to 30 days after the last application of study medication.

        Clinical diagnosis of alopecia areata or other non AGA forms of alopecia. Scalp hair loss
        on the treatment area, due to disease, injury or medical therapy.

        Active skin disease of the scalp (such as psoriasis or seborrheic dermatitis) or a history
        of skin disease on the scalp that in the opinion of the investigator would interfere with
        the study assessments or efficacy or safety. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Shanler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aclaris Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy Schnyder</last_name>
    <phone>484-329-2144</phone>
    <email>jschnyder@aclaristx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aclaris Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aclaris Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aclaris Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

